Aroa BiosurgeryASX:ARX +0.85%62 PB Ratio is 2.46 as of Jun. 26, 2026, which is 14% below its 10-year median of 2.86. GuruFocus rates ASX:ARX with a GF Score™ of 62/100 and a GF Value™ of A$0.80 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Aroa Biosurgery ranks worse than 56.6% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Aroa Biosurgery's share price is A$0.59. Aroa Biosurgery's Book Value per Share for the quarter that ended in Mar. 2026 was A$0.24. Hence, Aroa Biosurgery's PB Ratio of today is 2.46.
The historical rank and industry rank for Aroa Biosurgery's PB Ratio or its related term are showing as below:
ASX:ARX'
s PB Ratio Range Over the Past 10 Years
Min: 1.59 Med: 2.86 Max: 6.93
Current: 2.47
During the past 7 years, Aroa Biosurgery's highest PB Ratio was 6.93. The lowest was 1.59. And the median was 2.86.
ASX:ARX's PB Ratio is ranked worse than 56.6% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs ASX:ARX: 2.47
During the past 12 months, Aroa Biosurgery's average Book Value Per Share Growth Rate was -2.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -4.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 3.00% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Aroa Biosurgery was 12.20% per year. The lowest was -4.80% per year. And the median was 3.25% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Aroa Biosurgery PB Ratio Related Terms
Aroa Biosurgery PB Ratio Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aroa Biosurgery's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's PB Ratio distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Aroa Biosurgery's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Aroa Biosurgery (ASX:ARX) has a PB Ratio of 2.46 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aroa Biosurgery and its competitors. This is 14% below median its historical median of 2.86. Over the past decade, Aroa Biosurgery's PB Ratio has ranged from 1.59 to 6.93. According to the industry distribution chart, Aroa Biosurgery ranks #446 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 56.6%.
Is Aroa Biosurgery's PB Ratio too high?
Aroa Biosurgery's current PB Ratio of 2.46 is 14% below median its 10-year median of 2.86. Over the past 10 years, this metric has ranged from a low of 1.59 to a high of 6.93. The Medical Devices & Instruments industry median PB Ratio is 2.02. Aroa Biosurgery's value of 2.46 is 21.8% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #446 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #446 out of 788 companies for PB Ratio. This places Aroa Biosurgery in the lower half of its industry. The industry median PB Ratio is 2.02. Aroa Biosurgery's value of 2.46 is 21.8% above this benchmark. Historically, Aroa Biosurgery's own PB Ratio has ranged from 1.59 to 6.93 over the past decade. While the company's 10-year median is 2.86 vs. the industry median of 2.02, Aroa Biosurgery has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current PB Ratio of 2.46 is 21.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current PB Ratio is 2.46, which is 14% below median its own 10-year median of 2.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current PB Ratio is 2.46, which is 14% below median its 10-year median of 2.86 and 21.8% above the Medical Devices & Instruments industry median of 2.02. Aroa Biosurgery's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current PB Ratio is 2.46 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
PB Ratio: 2.46 (14% below median its 10-year median of 2.86)
GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
Industry Position: 21.8% above the Medical Devices & Instruments median (#446 of 788)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score
Get the complete analysis for ASX:ARX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
